BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, February 11, 2026
Home » Authors » Tom Wall

Tom Wall

Articles

ARTICLES

FDA's Request Shakes Up Vivus Stock, Qnexa Timeline

Jan. 24, 2011
By Tom Wall
A week after Vivus Inc. CEO Leland Wilson praised the FDA during a breakout session at the J.P. Morgan Healthcare conference, the agency's request for more data about the incidence of birth defects in children born to women using topiramate, a component in obesity treatment Qnexa (phentermine/topiramate), shook the company's stock and plans for August FDA approval and a late 2011 launch.
Read More

Ardea Follows Positive Gout Results with $71.5M Offering

Jan. 21, 2011
By Tom Wall
January already had been a pretty good month for Ardea Biosciences Inc. and it got even better on Thursday.
Read More

Orexigen Nears PDUFA as Vivus, Arena Keep Trying

Jan. 14, 2011
By Tom Wall
SAN FRANCISCO – If there was a trifecta for biotechs developing new weight-loss therapies, presentations by Vivus Inc., Orexigen Therapeutics Inc. and Arena Pharmaceuticals Inc. Wednesday at the J.P. Morgan Healthcare conference would have given you a pretty good idea of who to pick for win, place and show.
Read More

Biogen's Strategy Picks Big Biotech over Small Pharma

Jan. 13, 2011
By Tom Wall
SAN FRANCISCO – Not long after George Scangos took over as Biogen Idec Inc. CEO last summer, he felt the need to clarify the company's culture. "We can be small pharma or a big biotech," he told attendees at the J. P. Morgan Healthcare conference during a late Tuesday presentation.
Read More

Genzyme Has Record Quarter, Mum on Sanofi Takeover Bid

Jan. 12, 2011
By Tom Wall
SAN FRANCISCO – Before there even was a J.P. Morgan Healthcare conference – and this is the 29th – there was Amgen Inc., founded in 1980, and Genzyme Corp., founded in 1981. When two of the corporate godfathers of biotech present on the same morning, people take notice; it's the industry's version of Arnold Palmer and Gary Player hitting honorary tee shots at the Master's.
Read More

Cephalon CEO Says Revascor Stem Cell Data 'Compelling'

Jan. 12, 2011
By Tom Wall
SAN FRANCISCO – Cephalon Inc.'s new CEO J. Kevin Buchi told attendees at the J.P. Morgan Healthcare conference that he knew what many people would think when they saw a press release about positive interim results from an ongoing multicenter Phase II trial of its "off-the-shelf" adult stem cell product Revascor for patients with congestive heart failure.
Read More

Symphogen Financing Largest for Private European Biotech

Jan. 12, 2011
By Tom Wall

Santaris and Pfizer Agree to $614M RNA Collaboration

Jan. 12, 2011
By Tom Wall

Big J.P. Morgan Turnout Reason for Optimism and Grumbling

Jan. 11, 2011
By Tom Wall
SAN FRANCISCO – The good news was that the 29th Annual J.P. Morgan Healthcare Conference kicked off Monday in San Francisco with 8,680 registered attendees, 1,400 more than last year – a sign that economic recovery is, if not here, then maybe not far away.
Read More

Biotech Mood, Activity Look Up as J.P. Morgan's Under Way

Jan. 10, 2011
By Tom Wall
SAN FRANCISCO – The mood of the biotech sector is "up," and with it avid participation is anticipated at the annual J.P. Morgan Healthcare conference, which kicks off here today and runs through Thursday.
Read More
View All Articles by Tom Wall

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 10, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing